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This report presents highlights from The National Lung Cancer
Partnership’s Annual Meeting, held in June 2007 in Chicago. It
discusses recent refinements in the histologic, genetic, and epige-
netic subtyping of lung cancers and suggests reasons why certain
therapies benefit only a subset of lung cancer patients. It also
describes new molecular data about the subtype-specific differences
in drug resistance among bronchioloalveolar-associated non-small
cell lung cancers and discusses strategies to avoid or tackle specific
drug-resistant tumors. Finally, it describes new findings about epi-
genetic differences—specifically in DNA hypermethylation—
among lung tumors, including some male/female differences, which
may prove useful as biomarkers for diagnosis, prognosis, and
prediction of response to treatments.
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(J Thorac Oncol. 2008;3: 190–193)
Unlike Gertrude Stein’s notion about a rose, lung cancer isnot lung cancer is not lung cancer. Researchers now
divide lung cancers into increasingly diverse subtypes, using
cellular and molecular diagnostic techniques. Categorizing
the cancers helps to explain current treatment limitations and
then to design more personalized and effective treatments.
Several presentations at the Annual Meeting of the
National Lung Cancer Partnership, held in Chicago on June 1,
2007, described using cellular, genetic, and epigenetic data to
inform the diagnosis of lung cancer, and the development of
new treatments. Highlights of those presentations are below.
UNDERSTANDING DRUG RESISTANCE AND
HOW TO OVERCOME IT
Far too often, anticancer drug treatment selects for cells
that circumvent the drug’s growth-inhibitory effects, and the
cancer returns. Drug resistance may be avoided by starting
with “cocktail” treatments employing multiple agents simul-
taneously, before drug-resistant cells have formed. The ques-
tion is: Which drug cocktail will best treat each cancer while
doing the least harm to the patient?
Hunting for a Broad-Spectrum Drug Cocktail
Against Lung Cancer
The National Lung Cancer Partnership/Lung Cancer
Online Foundation Career Development Award winner, Hay-
ley McDaid, PhD (Albert Einstein College of Medicine), is
exploiting the cellular dysregulation that occurs in lung can-
cer. She is targeting key pathways that communicate during
growth-regulatory signaling by identifying aberrantly regu-
lated genes that drive tumor growth in individual types of
lung cancers.
First, McDaid compiled a list of the most common lung
cancer mutations in the Catalog of Somatic Mutations in
Cancer database.1 Lung cancer is genetically heterogeneous,
but distinct histologic types show genetic similarity. One
type, mucinous bronchioloalveolar carcinoma (BAC), typi-
cally carries Kirsten rat sarcoma (KRAS ) virus oncogene
mutations, which are oncogenic. KRAS participates in mito-
gen-activated protein kinase signaling to regulate cell growth,
differentiation, and senescence (Figure 1, right-hand path-
way). Drugs that inhibit pathway activities downstream of
KRAS could be useful for treating tumors. This idea has led
to new therapies targeted at MEK (MAP-ERK kinase, a MAP
kinase kinase), which acts downstream of KRAS (Figure 1,
right-hand pathway).
Drug-Induced Adaptation in Cancer Helps to
Predict Novel Drug Combinations
McDaid et al. showed that treating some cell lines with
paclitaxel led to increased activity of MEK substrates extra-
cellular signal-regulated kinases (ERK1 and ERK2). The
researchers hypothesized that the ERK1/2 increase was a
stress response, counteracting the death-inducing effects of
paclitaxel. Paclitaxel together with the MEK inhibitor CI-
1040 additively killed ERK-expressing cells.2 ERK-express-
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ing human lung tumors grown in mice were similarly sensi-
tive to the drug cocktail. These in vivo effects were transient;
over time, tumors reappeared. McDaid then asked what
components of the signaling network (Figure 1) might over-
ride the effects of CI-1040, with the goal of identifying a drug
to combine with the MEK inhibitor to treat lung cancers.
When MEK Inhibitors Do Not Suffice, Look to
Mammalian Target of Rapamycin (mTOR)
Inhibition as Well
McDaid found that MEK inhibitor-treated lung cancer
cells had increased activity of the protein cellular homolog of
viral oncogene isolated from T-cell lymphoma in AKR
mouse strain (AKT). AKT acts within the phosphoinositide
3-kinase pathway, which also controls growth and differen-
tiation, and often becomes dysregulated in cancer (Figure 1,
left-hand pathway). Importantly, AKT interacts with mito-
gen-activated protein kinase pathway components,3 forming a
signaling network that integrates cellular growth processes.
Knowing that AKT increased in the presence of the
MEK inhibitor, but lacking an AKT inhibitor suitable for
testing in human cells, McDaid tested rapamycin in combi-
nation with CI-1040. Rapamycin inhibits mTOR, which acts
downstream of AKT (Figure 1, left-hand pathway). She
reported that the two agents synergized to halt proliferation of
many lung cancer cell lines by causing G0/G1 arrest.
The Drug Combination Blocks
Protein Synthesis
McDaid then found that the mTOR and MEK inhibitors
cooperatively blocked at least two proteins: 4E-BP1 and
ribosomal protein S6, which recruit ribosomes to mRNAs,
thus regulating protein synthesis. McDaid also tested the
MEK and mTOR inhibitors in several mouse models of lung
cancer that have different mutations. Even when the individ-
ual drugs permitted tumor growth, the combination inhibited
tumor growth. These studies used low drug doses, which the
mice tolerated well.
McDaid believes that, in signaling networks, inhibiting
one axis (e.g., MEK) is insufficient because other compo-
nents (e.g., AKT and mTOR) compensate, causing resistance.
Because the selected drug combination targets connected
pathways that frequently become dysregulated in lung cancer,
it could successfully treat lung cancers with a broad range of
mutations in the retrovirus associated sequence and AKT
pathways.
BAC: CLINICAL, SCIENTIFIC, AND
PATHOLOGIST PERSPECTIVES
Several features of BAC made it an important focus for
a panel discussion at this year’s National Lung Cancer Part-
nership meeting. Genetically, BAC seems to have many
fewer mutations than other non-small cell lung cancers
(NSCLCs). Moreover, KRAS mutations—hallmarks of smok-
ing-related lung cancer—are rare among the nonmucinous
subtype of BAC tumors. Instead, somatic epidermal growth
factor receptor (EGFR) mutations predominate in BAC. Non-
mucinous BAC also shows a weaker link with a history of
smoking than do NSCLCs lacking evidence of BAC. Other
demographic factors that set BAC apart from other NSCLCs
include its higher prevalence among women and individuals
in Japan.
The World Health Organization classifies BAC as hav-
ing lepidic growth along alveolar walls, and lacking signs of
invasion, necrotic cores, or papillary structures.4 Fewer than
4% of lung cancer patients have pure BAC and they have a
5-year survival of 100%, said Elizabeth Brambilla, MD,
PhD (Universite´ Joseph Fourier). However, Brambilla noted
that pathologists find BAC components in 50% of adeno-
carcinomas, a main class of NSCLCs. Moreover, combining
histologic, molecular, and high-resolution CT data, research-
ers can distinguish mucinous from nonmucinous lesions in
BAC. These distinctions may aid in diagnosis, prognosis, and
treatment.
From Clinically Striking Anecdotes to
Systematic Studies
Vincent Miller, MD (Memorial Sloan-Kettering Cancer
Center), described a clinical response in an individual patient
so striking that it moved BAC into the limelight. As the
treating physician for one of the first lung cancer patients to
respond favorably to the drug gefitinib, Miller explained that
this never-smoking male was profoundly symptomatic on
entering the study. Within days of starting gefitinib, an
EGRF-selective tyrosine kinase inhibitor (EGFR-TKI), the
patient felt markedly better. Radiographs confirmed that his
lung mass had shrunk markedly. A few more such uncommon
responses to gefitinib and erlotinib, the other oral EGFR-TKI,
hinted that this drug sensitivity was because of a distinct
molecular fingerprint. Subsequent research found that the
EGFR-TKI responders typically had a somatic mutation in
EGFR. Several different EGFR mutations were found, with
most causing ligand-independent activation of the receptor’s
tyrosine kinase domain. Tumors from many of the drug
responders had BAC components.
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FIGURE 1. Combining MEK and mTOR inhibitors in lung
cancer. Components of the RAS-AKT signaling network con-
verge at many levels to control translation, mitogenesis, dif-
ferentiation, and senescence. The mTOR inhibitor rapamycin
and the MEK inhibitor PD0325901 (a derivative of CI-1040)
act synergistically to inhibit cell proliferation in human lung
cancer cell lines.
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Looking for Survival Factors in EGFR-TKI
Treatment Studies
Because only some BAC patients in the early studies
responded favorably to the EGFR-TKIs, Miller wanted to
know what set these patients apart. In a phase II erlotinib trial
in patients with adenocarcinoma with significant BAC or pure
BAC, patients with EGFR mutations in exon 19 or 21 carried
an 80% chance of responding to erlotinib and a long
survival. Conversely, patients whose tumors harbored KRAS
mutations never responded to erlotinib and survival was
shorter. This example, Miller noted, showed how molecular
markers complement histologic findings to improve progno-
sis and treatment.
Understanding the EGFR Mutations in BAC
Pasi Ja¨nne, MD, PhD (Dana Farber Cancer Institute),
discussed the therapeutic implications of somatic mutations
in BAC. Pointing to the EGFR exons 19 and 21 mutations, he
explained that both are associated with strong positive re-
sponses to the TKI drugs. Both these EGFR mutations change
the shape of the pocket in which ATP and the TKI drugs bind
to the protein and increase the affinity of gefitinib for the
mutant form of EGFR.
Amplified EGFR, and in particular, amplified mutant
EGFR, has also been observed in BAC, according to Ja¨nne
and Miller. High EGFR copy number has been linked to
increased survival in TKI-treated BAC patients. Upcoming
prospective trials will include evidence of EGFR gene am-
plification as an enrollment criterion, Ja¨nne said.
Upon classifying BAC-containing tumors into muci-
nous or nonmucinous subtypes, Ja¨nne found that EGFR
mutations and amplifications were common in the nonmu-
cinous tumors but rare in the mucinous ones, and the
opposite is the case for KRAS mutations. This association
between genetics and histopathology may prove useful in
selecting potentially responsive patients for the EGFR-
specific drugs.
Drug Resistance: An Eventual Outcome of
EGFR-TKI Treatment
Although EGFR-TKIs helped BAC patients with
abnormally activated EGFR for a while, all the cancers
returned, and were EGFR-TKI resistant. Drug resistance in
50% of cases studied stemmed from a new EGFR kinase
domain mutation. Moreover, 50% of patients with TKI-
resistant tumors had the same new mutation, T790M. This
mutation reduces the drugs’ affinity for the protein. Be-
cause the same mutation occurred so frequently, research-
ers are now developing drugs that bind irreversibly to
EGFR containing both the original and resistance-causing
mutations. Following encouraging preclinical studies, clin-
ical trials of such compounds are underway or being
planned.
Ja¨nne’s group found other mutations that, like the
T790M change, render BAC tumors EGFR-TKI resistant.
One culprit may be an amplified mesenchymal epithelial
transition factor (MET ) gene. The researchers found this
change after inducing EGFR-TKI resistance in previously
drug-sensitive cells in vitro. By subsequently inhibiting MET
activity in these cells, they restored EGFR-TKI sensitivity. In
human tumors that were EGFR-TKI resistant but did not have
the T790M mutation, they found that about 1/4 of them had
MET gene amplification.5 These results offer another inroad
into targeted combination drug therapy to treat specific types
of lung cancer.
EPIGENETICS AND SEX DIFFERENCES IN
LUNG CANCER
The hunt for the molecular bases of cancer has high-
lighted DNA sequence changes—either heritable genetic
mutations that increase the risk for cancer, or spontaneously
arising somatic mutations. However, tumorigenesis involves
more than genetic changes.
Methylation—An Epigenetic Decoration of
DNA that can Silence Genes
As National Lung Cancer Partnership Research Grant
winner, Christoph Plass, PhD (Ohio State University) ex-
plained, epigenetic changes also may participate in carcino-
genesis. Specifically, DNA methylation at certain cytosines
increases in cancer. When increased methylation occurs in
gene promoter regions, those genes may be silenced because
of chromatic structure changes. Presumably, the newly si-
lenced genes in cancers include some that limit cell division
or lifespan.
Homing in on Cancer-Specific DNA
Methylation
Researchers frequently find differences in DNA
methylation between cancers and their normal counter-
parts. Recently, scientists have found ways to simulta-
neously reveal the methylation status of hundreds of pro-
moter sites. Using one such approach, Plass et al. analyzed
the DNA methylation patterns from human adenocarcino-
mas and squamous cell carcinomas and from paired normal
lung tissue. The researchers looked for molecular biomar-
kers that distinguished between the two subtypes of
NSCLC because the subtypes may differ in their responses
to various therapies.
After identifying numerous cancer-related methylation
changes, Plass et al. focused on a few dozen DNA sites that
were most frequently hypermethylated in the lung cancers
sampled. Blinded to tumor type, the investigators performed
cluster analysis to group tumors according to similarity of
methylation patterns. The researchers found that the meth-
ylation patterns were subtype specific; i.e., adenocarcino-
mas resembled each other and squamous cell carcinoma
samples resembled each other more than they each resem-
bled tumors of the other subtype. Moreover, most of the
methylation sites fell in or near gene promoters, and
therefore potentially marked cancer-specific changes in
expression of those genes.
A closer look at one gene with a hypermethylated
promoter, called Olig1, showed that Olig1 protein expression
levels in tumors directly correlated with patient survival time.
Thus, Olig1 expression, or the methylation status of its gene,
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might become a marker for diagnosis, prognosis, and treat-
ment recommendations.6
Male-Female Difference in Lung Tumor DNA
Methylation Patterns
Plass et al. are comparing DNA methylation patterns of
lung tumors in men and women. Using cluster analysis of
hypermethylated DNA sites in lung tumors, they obtained
preliminary evidence that hypermethylation patterns in lung
tumors from men resembled each other and those from
women resembled each other more than they resembled
tumors from the opposite sex.
The investigators then sequenced the DNA fragments
containing these male- or female-specific hypermethylated
sites. Surprisingly, many fragments contained estrogen re-
sponse elements (EREs), which are sites where estrogen
receptors specifically bind. The presence of EREs in tumor-
specific hypermethylated DNA sites was not restricted to sites
from tumors in women; EREs also appeared in sites that were
selectively hypermethylated in tumors from men.
If cancer development involves sequential changes,
starting with a loss of specific transcription regulatory factors
(such as the estrogen receptor) from chromatin, and that loss
makes the DNA vulnerable to methylation, then gene silenc-
ing can occur. Plass et al. will be testing whether the enrich-
ment of EREs that often become hypermethylated in lung
cancers is significant in this process.
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